A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.
R MösgesE M KascheEsther RaskopfJ SinghL SohlichA AstvatsatourovK Shah-HosseiniS PirottonL HaazenS R DurhamT LegonG ZadoyanM H Mohamed ShamjiPublished in: Allergy (2017)
Three-week immunotherapy with 170 μg LPP reduced CPT reactivity significantly and increased protective specific antibodies.